ESTRO 2025 - Abstract Book

S3908

Radiobiology - Microenvironment

ESTRO 2025

Fig.1 Disease free survival in breast cancer patients according to AH consumption

Conclusion: We can conclude with these results that there is a potential benefit in the use of antihistamines by improving long term outcomes for patients. These findings warrant further investigation into the potential role of antihistamines as a co-adjuvant in improving long-term cancer outcomes. Given the positive association observed, additional prospective studies are needed to confirm these results and could potentially lead to new therapeutic strategies for enhancing disease management and survival rates.

Keywords: antihistamines, breast cancer, survival

References: 1. Liu X, Zhong R, Huang J, Chen Z, Xu H, Lin L, et al. Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer. J Exp Clin Cancer Res [Internet]. 2024;43(1):5. 2. Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol [Internet]. 2021;14(4):101029. 3. Fritz I, Wagner P, Broberg P, Einefors R, Olsson H. Desloratadine and loratadine stand out among common H1 antihistamines for association with improved breast cancer survival. Acta Oncol [Internet]. 2020;59(9):1103–9.